Answer
Breastfeeding should be discontinued during zanubrutinib (Brukinsa) treatment because it is unknown whether zanubrutinib or its metabolites enter human milk and a risk to breastfed children cannot be excluded.
Sources for this answer
- BRUKINSA 80 mg hard capsulesBeOne Medicines UK, Ltd. · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 8Document updated
Sources checked